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others.[1,2] EVs are highly heterogeneous, 
and can be divided based on their origin 
into exosomes, microvesicles, and apop-
totic bodies.[2,3] Exosomes are small EVs of 
40–100  nm diameter released by the back-
fusion of multivesicular bodies (MVB) with 
the plasma membrane.[4,5] Microvesicles are 
a heterogeneous population of EVs with a 
diameter of ≈100–500 nm, budding directly 
from the cell membrane in response to 
various stimuli.[3] Apoptotic bodies are 
products of the programmed cell death and 
are represented by a heterogeneous popu-
lation of large vesicles with 400–3000  nm 
diameter, containing different components 
including residual organelles. Despite their 
different origin, exosomes, and microvesi-
cles may harbor similar surface proteins 
and available isolation technologies do not 
allow their separation. Therefore, for both, 
the generic term “EV” was suggested in the 
community.[2] In this work, we will focus 
on a population of small EVs and describe 
a new method for their capture. Consistent with the minimal 
information for studies of EVs (MISEV2018) guideline, we deter-
mine and characterize these vesicles as “extracellular vesicles 
(EVs),”[2] and will use this term in this manuscript.
Recent achievements in cancer research demonstrated, that 
EVs play a highly important role in diseases progression, e.g., 
by organ-specific preparation of the premetastatic niche.[6] 
Extracellular vesicles (EVs) contain various bioactive molecules such as 
DNA, RNA, and proteins, and play a key role in the regulation of cancer 
progression. Furthermore, cancer-associated EVs carry specific biomarkers 
and can be used in liquid biopsy for cancer detection. However, it is still 
technically challenging and time consuming to detect or isolate cancer-
associated EVs from complex biofluids (e.g., blood). Here, a novel EV-capture 
strategy based on dip-pen nanolithography generated microarrays of 
supported lipid membranes is presented. These arrays carry specific 
antibodies recognizing EV- and cancer-specific surface biomarkers, enabling 
highly selective and efficient capture. Importantly, it is shown that the 
nucleic acid cargo of captured EVs is retained on the lipid array, providing 
the potential for downstream analysis. Finally, the feasibility of EV capture 
from patient sera is demonstrated. The demonstrated platform offers rapid 
capture, high specificity, and sensitivity, with only a small need in analyte 
volume and without additional purification steps. The platform is applied 
in context of cancer-associated EVs, but it can easily be adapted to other 
diagnostic EV targets by use of corresponding antibodies.
1. Introduction
Extracellular vesicles (EVs) are lipid-bilayer enclosed structures 
shed by nearly all cells of a human body, containing abundant 
information about the cell of origin in form of proteins, RNA and 
DNA. They play an important role for cell–cell communication 
and present in all body fluids, like blood, urine, milk, tears, and 
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As cancer is the second most common cause of death in devel-
oped countries, cancer diagnosis and treatment became one 
of the most important tasks of modern medicine.[7] However, 
despite of the progress and acquired knowledge, the immi-
nent need for new tools for early detection of cancer and new 
therapeutic strategies remains challenging.[8–10] Recent findings 
show that cancer cells produce significantly more EVs than 
healthy cells and use EVs for the regulation of the local tumor 
microenvironment as well as distant sites, promote vasculogen-
esis, immune suppression, tumor growth, and metastasis.[11–14] 
These cancer-associated EVs are promising biomarkers for 
early cancer detection and therapy monitoring,[15–19] as well 
as therapy itself,[20,21] and can be used in proteomics.[22] How-
ever, as for their small size, high heterogeneity, and the com-
plex background of other components present in body fluids, 
detection and isolation of EVs still pose a considerable chal-
lenge.[19,23] No clinically approved method for EV detection 
exists. In clinical use, such method should be accurate, specific, 
reproducible, rapid, easy to handle, cheap, and applicable for 
different types of EVs.[24]
2. Results and Discussion
2.1. The Lipid Microarray Based EV Capture Platform
In order to address the challenges of EV capture, we propose 
to exploit the unique interaction of biomolecules and biological 
membranes with biomimetic supported lipid membranes 
(SLMs)[25] for a novel lipid microarray based strategy (Figure 1). 
Two defining factors make SLMs ideal for this approach: First, 
they retain lipid dynamics (meaning the diffusion of lipid com-
ponents within the membrane) which are the basis of many inter-
actions in natural lipid membranes, such as signaling, transport 
and cell–cell contact. Second, pure lipid SLMs have intrinsic non-
fouling properties (i.e., are protein and/or cell repellant).[26] Both 
features allow the proposed SLM microarrays to become highly 
sensitive and accurate biosensors. In order to produce SLM micro-
arrays, we employ lipid dip-pen nanolithography (L-DPN), which 
enables patterning of micro- and nanoscale-sized lipid patches on 
various substrates in a multiplexed manner (i.e., different compo-
sitions of lipid within one array).[27–30] First, lipid membranes of 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) with a 5 mol% 
admixing of the biotinylated phospholipid 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine-N-(cap  biotinyl) (Biotin-PE) are written 
via L-DPN (Figure 1a). Then these are incubated with streptavidin 
solution to provide binding sites for biotinylated antibodies (ABs) 
(Figure  1b). Specific biotinylated ABs recognizing cancer-associ-
ated EVs are incubated with the array and self-assemble onto the 
lipid patches (Figure  1c). The ABs can also be delivered to indi-
vidual patches by spotting techniques, in case multiplexed detec-
tion arrays are desired.[31] When the arrays are exposed to liquids 
containing EVs carrying the targeted surface markers, these will 
attach to the lipid patches carrying matching ABs (Figure 1d). In 
addition to the mere attachment, the SLM-based approach allows 
for membrane fusion taking place between captured EVs and 
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Figure 1. Scheme of extracellular vesicle (EV) capture by supporting lipid membranes (SLM). a) Fabrication of biotinylated SLM arrays by L-DPN. b) 
Coating of the SLM arrays with streptavidin. c) Binding of biotinylated antibodies on the SLM arrays. d) Capture of cancer-associated EVs on SLM 
arrays. e) Fusion of captured EVs with the SLM. f) Trapping of EV-derived biomaterials (e.g., RNA, proteins) by the SLM.
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the lipid patches in the array (Figure  1e). In natural membrane 
fusion,[32] van der Waals attraction and/or membrane proteins 
bring two lipid membranes close together leading to increased 
membrane disorder, defects occurring in the bilayers then lead to 
final fusion.[33] Albeit the molecular mechanisms of EV uptake by 
the target cells are not fully discovered, one of the possible mecha-
nisms, suggested is fusion. To allow the EV to fuse with the cell 
membrane, an EV should be kept in a close proximity to the 
membrane of the recipient cell. It is suggested, that SNARE and 
Syncytin-2 may be involved in the membrane fusion;[34–37] none-
theless, it is assumed, that contact of EV with the cell membrane 
may be sufficient to initiate fusion.[38,39] In our platform, the mem-
brane bound ABs, therefore, are not only ensuring specificity of 
EV capture, but also promote membrane fusion and enhance the 
trapping processes, by holding the EV in near vicinity to the lipid 
patch. Finally, the membrane fusion process leads to trapping of 
EV cargo into the membrane patch (Figure 1f), which may open 
the route to further downstream analysis of the cancer-related 
genome and proteome. The platform is free in choice of ABs and 
thus very flexible in the desired target. Recently, more and more 
biomarker-proteins of cancer-EVs are discovered,[40] improving 
the precision and specificity of immunoaffinity-based techniques 
for EV capture. Generally, these techniques are fast, efficient, and 
require only a small amount of analyte, making them applicable 
in clinical routine.[41] ABs can be chosen from a library of available 
options to address specific needs in regard to the targeted EVs. 
Several tetraspanins, in particular CD9, CD63, and CD81, were 
found to be enriched on the majority of EVs and thus are fre-
quently used as generic EV biomarker. In many cancer-associated 
EVs, the epithelial cell adhesion molecule (EpCAM) was identi-
fied.[15] Therefore, CD63 and EpCAM were selected in this study 
as general and as cancer-specific EV biomarker respectively.
2.2. Capture of Cancer-Associated EVs by SLM Arrays
To establish a proof-of-concept for the platform, EVs from the 
conditional medium of the broadly used breast cancer line 
MCF7[42] were utilized. To obtain standardized material for 
experimentation, small EVs were purified using size exclu-
sion chromatography (SEC) and characterized according to 
the MISEV guidelines.[2] The fractions 1–4 obtained from SEC 
were collected to determine the EV-enriched fraction. For that, 
the protein content and number of particles were measured by 
micro bicinchoninic acid assay (BCA) and nanoparticle tracking 
analysis (NTA), respectively (Figure 2a).
Following recommendations of manufacturer we selected 
fraction 2, exhibiting the highest number of particles and 
(as  all fractions 1–4) a low amount of protein. In order to vis-
ualize the EVs in fluorescence microscopy, they were stained 
with a lipophilic dye (PKH26, red fluorescent), and incubated 
to lipid microarrays functionalized with CD63 and EpCAM 
ABs (Figure  2b). The lipid patches of the array exhibit red 
fluorescence in the presence of EVs bound either to CD63 
or EpCAM, while lipid patches carrying isotype control ABs 
(immunoglobulin G (IgG)1) remain dark (Figure  2b). This 
shows that the lipid array can capture EVs by specific surface 
biomarkers (CD63 or EpCAM), while no fusion occurs when 
no matching biomarker is present on the EV (as seen on the 
sample containing the IgG1 isotype control). As the used dye 
is lipophilic, an additional control experiment was performed 
to ensure that the positive fluorescence signals on the lipid 
array are not caused by PKH dye not bound to EVs or detaching 
from the EVs and diffusing toward the array. For this, purified 
and stained EVs were incubated on a lipid array consisting of 
patches with pure DOPC on one side as negative control and 
Biotin-PE/DOPC and AB functionalized patches on the other 
side. Here, as expected, only the AB-functionalized patches 
emit the fluorescence signal, while the DOPC-only patches 
remain dark (Figure S1, Supporting Information). This obser-
vation supports the specificity of the visualized fluorescence 
signal, indicating a binding of labeled EVs to the AB-functional-
ized patches. Furthermore, this experiment highlights the anti-
fouling property of the lipid layer, as the DOPC patches appear 
even darker then the surrounding nonfunctionalized glass-slide 
surface, on which unspecific random adhesion of some of the 
stained EVs may take place. As an additional control, other SEC 
fractions were incubated on AB-functionalized lipid microar-
rays. As expected, no significant fluorescence signal is observed 
on any of the patches functionalized with CD63, EpCAM ABs, 
or the IgG1 isotype control, supporting on the one hand the 
quality of EV isolation and on the other hand the specificity of 
the SLM-based EV detection (Figure S2, Supporting Informa-
tion). In combination, these results show that the lipid micro-
array platform can effectively capture EVs purified from the 
conditional medium of MCF7 cells as a proof-of-concept.
2.3. Specificity of EV Capture
Clinical samples, such as blood samples, contain various EVs 
originating from different cell types, therefore, specific detection 
of tumor-derived EVs is crucial for a robust diagnosis. To explore 
the specificity of our device, purified EVs from three different cell 
lines (MCF7, HT1080, and 3T3 fibroblast) were trialed. As a gen-
eral EV biomarker, CD63 should be present on EVs released by 
any of the three cell lines.[43–47] In contrast, only MCF7 (a breast 
cancer cell line of epithelial origin), but not HT1080 (a nonepi-
thelial fibrosarcoma cell line) express EpCAM,[48] as confirmed by 
fluorescence-activated cell sorting (FACS) (Figure S3, Supporting 
Information). When incubating the respective EVs on AB-func-
tionalized lipid microarrays, the fluorescence signals reveal the 
described specificity (Figure 3). All three types of EVs are cap-
tured on the CD63 functionalized lipid patches. In contrast, only 
the MCF7-derived EVs are captured on EpCAM-functionalized 
lipid patches. For the IgG1 isotype control AB none of the EV 
types is captured (as expected from the negative control). The 
results show, that by choice of adequate AB, the platform can 
specifically capture a certain type of EV.
2.4. Sensitivity of EV Capture
In order to investigate the sensitivity of our platform, EV dilution 
series were conducted for lipid microarrays functionalized with 
three different ABs (against CD9, CD63, and EpCAM, respec-
tively). The concentration of MCF7-derived EVs in nine purified 
samples from independently collected cell culture medium was 
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quantified by ExoELISA to be (3.7 ± 2.2) × 1010 particles mL−1. The 
initial sample was diluted by a factor of 10 to obtain a starting point 
with ≈4 ×  109 EVs mL−1 for a dilution series in the physiological 
relevant range of EV abundance (103–109 mL−1) in patient blood.[49] 
This sample range (4 ×  109 to 4 ×  103 EVs mL−1) was then incu-
bated onto lipid arrays functionalized with different capture ABs.
The obtained fluorescence signals show that detection is still 
possible down to 1: 104 dilution (translating to 5 × 105 EVs mL−1) 
for CD63 ABs and even in a 1:106 dilution (translating to 
5 × 103 EVs mL−1) for the EpCAM and CD9 ABs (Figure 4), thus 
demonstrating the high sensitivity in the relevant EV concen-
tration range. Additionally, the differences between the three 
ABs underline, that choice of an optimal AB is key for an effi-
cient capture and maximal sensitivity.
2.5. Characterization of AB Immobilization
To further characterize the platform, we strived to look at the 
immobilization density and role of the lipid membrane fluidity 
Adv. Mater. 2021, 2008493
Figure 2. Capture of purified MCF7 EVs. a) Total protein amount (orange line) and concentrations of particles (blue bars) of fraction 1–4. Fraction 2 
(marked with *) was chosen for subsequent experiments as it contains the highest number of particles and low protein concentration, confirming EV 
enrichment in these fractions according to the manufacturer recommendations. The error bars are given as the standard error of the mean in 4 inde-
pendent samples. b) Consistent with the expectations, fraction 2 also leads to the strongest fluorescent signals (compared to the other fractions) on 
lipid patches harboring CD63 and EpCAM antibodies. Patches functionalized with IgG1 as isotype control show no fluorescent signal after incubation 
with fraction 2 (negative control). Scale bars equal 50 µm.
www.advmat.dewww.advancedsciencenews.com
2008493 (5 of 13) © 2021 The Authors. Advanced Materials published by Wiley-VCH GmbH
in the capture process. In order to investigate the average 
amount of immobilized ABs on a lipid patch, we used gold 
nanoparticle (Au-NP)-conjugated secondary ABs to detect the 
EV-capture ABs bound to the lipid patches. The Au-NPs were 
then visualized on the lipid patches by scanning transmission 
electron microscopy (STEM). The 2 nm Au-NPs are clearly vis-
ible in the obtained images (Figure 5).
As counting the particles on a whole 30 × 30 µm² lipid patch 
is not feasible, 10 smaller areas in two different magnifications 
and on different locations on a patch were scanned and the par-
ticles were identified and counted using ImageJ[50] (Figure S4, 
Supporting Information). The size of one AB is around 10 nm,[51] 
thus the Au-NPs (2 nm) are significantly smaller and should not 
sterically affect the binding density. Although we cannot fully 
exclude the possibility of double conjugation, it seems reasonable 
to assume that there is a 1:1 ratio of primary AB to secondary 
AB and conjugated Au-NP (or being at least of the same order). 
Following these assumptions, an average number of around 
5.1  ×  106 ABs per 30  ×  30  µm2 lipid patch, giving a density of 
5.7 × 103 µm−1. This is about a tenth of the number of accessible 
headgroups of a model allergen conjugated lipid in a lipid patch 
as estimated previously[52] when adjusted to the same concentra-
tion. Keeping in mind that each streptavidin (as tetramer with 
a total of four biotin-binding pockets, 2 each in opposite direc-
tions)[53,54] can potentially bind to biotinylated lipids at the mem-
brane facing side, but only one of the bigger biotinylated ABs on 
the other side for steric reasons and that conjugation efficiency 
of the AB attachment to the lipid patch and the secondary conju-
gation with the Au-NP carrying AB will both be not 100%, these 
results are still in reasonable agreement.
Adv. Mater. 2021, 2008493
Figure 3. Specificity of EV capture. a,b) Fluorescently labeled (red, PKH26 dye) MCF7-derived EVs are captured by CD63 (a) and EpCAM (b) antibody-
functionalized lipid patches. c) No capture is observed on lipid patches functionalized with IgG1 isotype control antibodies (negative control). d) 
Similarly, fluorescently labeled EVs (green, PKH67 dye) derived from HT1080 cells are captured by CD63-antibody-functionalized lipid patches. e) A 
minor signal of HT1080 EVs on the EpCAM-functionalized lipid patches was detected, indicating that high EV concentration may cause some unspecific 
capture. f) Again, no interaction with IgG1 isotype control antibodies carrying lipid patches is observed (negative control). g–i) Fluorescently labeled 
(green, PKH67 dye) 3T3-fibroblast-derived EVs are only captured on CD63 antibody-functionalized lipid patches (g) and not on EpCAM antibody-
functionalized lipid-patches (h), or IgG1 isotype control antibody-carrying lipid patches (negative control) (i). Scale bars equal 50 µm.
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In addition to the previously discussed AB density, the role 
of attachment to the lipid layer in capture effectiveness is of 
interest. Various strategies for AB immobilization are dis-
cussed in the literature, in particular focusing on how to mini-
mize the impact of linking strategy on AB function. While 
common chemical linking approaches, targeting amine-, car-
boxyl-, or thiol- groups usually work effortless, they cannot con-
trol the specific orientation of AB in relation to the surface, as 
these groups are available in abundance on the AB.[55–57] There-
fore, a fraction of the ABs will be oriented with their active site 
toward the surface, thus rendering them inactive for capture. 
Certain click-chemistry approaches as well as making use of 
biochemical interactions (e.g., streptavidin-biotin, protein A/G 
binding to ABs) can achieve an orientation-controlled immobi-
lization.[56] However, these approaches are usually more elabo-
rate, and, e.g., in the streptavidin-biotin strategy, also the ABs 
need to be biotinylated site-specifically, otherwise orientation is 
again random. All standard approaches have in common, that 
they bring the AB usually into very near vicinity to the surface 
with only a linker molecule in between. Therefore, it is of spe-
cial interest, that it is reported in the literature, that anchoring 
of ABs to lipid membranes enhances the capture of circulating 
tumor cells (CTC)[58,59] and that tuning membrane fluidity of 
liposomes can be used to specifically target cancer cells.[60] 
This points to a positive influence of such a “lipid cushion” on 
AB effectiveness in general. In contrast, commercial EV cap-
ture platforms like ExoView (Nanoview Biosciences, USA) and 
Exo-Check (System Biosciences, USA) and approaches using 
plasmonic sensors directly immobilize antibodies on their 
devices.[61–63] Therefore, we trialed our approach for the case 
of ABs directly bound to the solid substrate, leaving out the 
lipid-patch cushion. To bind the ABs directly to a substrate, a 
click-chemistry approach was used to generate surface bound 
Adv. Mater. 2021, 2008493
Figure 5. Antibody density on functionalized lipid patches. a,b) STEM images of an antibody-functionalized lipid patch after incubation with Au-NP 
conjugated secondary antibody. c) Close-up of the area marked with the green box in (b). At this magnification, single Au-NPs become discernable. d) 
EDX data on the particles within the red box of the inset, showing that the observed particles are indeed the Au-NPs. Based on the observed Au-NP 
density, 5.1 × 106 antibodies are expected per 30 × 30 µm² lipid patch (translating to a density of ≈5.7 × 103 µm−1).
Figure 4. EV capture sensitivity. The graph shows the obtained fluo-
rescence intensity on the lipid-patch array functionalized with different 
antibodies (CD9, CD63, and EpCAM, respectively) for undiluted purified 
MCF7-derived EVs (containing 4 × 109 EVs per mL) and dilutions of 1:102, 
1:104, and 1:106, containing 4 × 107, 4 × 105, 4 × 103 EVs per mL, respectively. 
The fluorescence intensity obtained with undiluted EVs is set to 1 for 
normalization. The error bars represent the SD from biological triplicates 
for each antibody.
www.advmat.dewww.advancedsciencenews.com
2008493 (7 of 13) © 2021 The Authors. Advanced Materials published by Wiley-VCH GmbH
biotin arrays as described previously.[64] In short, biotin-azide 
was spotted via microchannel cantilever spotting (μCS)[65] 
onto dibenzocyclooctyne (DBCO) functionalized glass slides. 
Then biotinylated ABs were bound via streptavidin as linker 
resulting in arrays analogue to the ones described above, but 
without the lipid patches in between bound ABs and glass 
surface. This allows for a side-by-side comparison of directly 
substrate-bound ABs (with only a short and rather rigid linker 
molecule between the glass and streptavidin/AB part of the 
sandwich) and the lipid-patch-based AB microarrays (with a 
full lipid membrane in fluid state between the streptavidin/
AB and the supporting solid glass substrate). After incubating 
CD63 AB-functionalized arrays of both types with fluores-
cently labeled EVs, the correlated fluorescence signal can only 
be detected on the lipid-based microarrays, while the direct 
substrate-bound sample only shows random attachment of 
EVs (Figure S5, Supporting Information). This striking dif-
ference can be accounted for by two reasons: (I) the mobility 
of lipid-linked ABs within a lipid patch, and (II) denaturation 
of ABs in direct contact to the solid substrate. Orientation sig-
nificantly affects the activity and efficiency of ABs and catalytic 
proteins.[66] Here, the lipid-membrane introduces a greater 
flexibility to the attachment, due to the membrane fluidity,[26,67] 
potentially mitigating accessibility problems. A similar effect 
was also reported in the capture of CTCs by lipid-conjugated 
ABs, where the capture efficiency decreased significantly 
(from 82.1% to 63.5%) after fluidity of the utilized SLMs was 
reduced.[59] Furthermore, the direct contact of the ABs with the 
solid surface can lead to denaturation and loss of function.[68] 
The nonfouling properties of the lipid patches can minimize 
the impact on AB structure, as they interact much less strongly 
with the bound AB as a glass surface.
2.6. EV Capture from Unpurified Samples and  
EV Cargo Retention
EVs are abundant in bodily fluids and cell culture medium. 
Thus, samples can be easily obtained, but these liquids also 
contain a vast complex background of other components, such 
as lipids, lipoproteins resembling in size and density the EV 
proteins, and cell debris.[23,69] Therefore, most EV capturing 
approaches strictly require prepurification or pre-enrichment 
steps, which are time-consuming and expensive. Encouraged 
by the good performance of our platform in the previous tests, 
experiments with unpurified cell medium were conducted. 
Here, MCF7 conditional medium was only prefiltered with a 
0.22  µm pore filter to remove cells or cell debris (>220  nm), 
which can be achieved in only 30 s. The filtered medium was 
then incubated on CD63 AB-carrying lipid microarrays for 
EV capture without further purification or enrichment steps. 
Because the EVs were also not fluorescently labeled for these 
experiments, a fluorescent labeled EpCAM AB was used for 
immunostaining of the lipid patches after EV capture. With this 
general setup, a series of different experiments was conducted 
to evidence the reliable capture of EVs directly out of a complex 
media background by the lipid microarray platform.
EV capture results showing a comparison of unpurified and 
purified samples are shown in Figure 6. The unpurified MCF7 
EVs show an even stronger EpCAM signal than the purified 
ones, probably because of damage and loss of EVs during the 
purifying steps. The HT1080 (as expected for being EpCAM 
negative) shows only a minimal fluorescent signal, caused by 
some remaining unspecific binding of the EpCAM-AB used 
for secondary staining. To even further raise sample com-
plexity and coming closer to a situation mimicking clinical 
samples, purified EVs of MCF7 were spiked into the condi-
tional medium of HT1080 cells (500 µL of purified MCF7 EVs 
into 12 mL of the conditional medium of HT1080). This results 
in the breast-cancer-associated EVs being in a vast background 
of EVs and other biomaterials stemming from nonbreast-
cancer cells, thus getting closer to a real clinical sample in 
complexity. Still, the lipid microarrays show a clear signal of 
captured EpCAM-positive EVs, thus indicating, that the MCF7 
EVs could be successfully captured from the spiked sample. 
The reduced intensity can be understood as caused by the 
additional dilution and preparation steps during spiking and 
competitive binding of the HT1080 EVs and MCF7 EVs onto 
the CD63 AB carrying lipid microarrays. To further ensure that 
the interpretation of the binding experiments is correct and no 
unspecific interference of other components in the medium 
occurs, additional control experiments were implemented 
(Figure S6, Supporting Information).
Finally, the aspect of retaining the EV cargo in the system 
was examined, as the EV content is a rich source of diagnostic 
and scientific information.[70] It was previously shown, that 
the content of EVs can be trapped on a surface when a SLM 
is formed by vesicle fusion of the EVs to the substrate.[71] To 
elucidate whether the EV cargo is also retained on our plat-
form, a RNA staining dye (SYTO RNASelect, only expressing 
green fluorescence when bound to RNA) was incubated onto 
the lipid microarrays after EV capture. Fluorescence sig-
nals were obtained from all lipid patches carrying CD63 AB 
(thus being able to capture EVs), while no fluorescence signal 
is detected on patches functionalized with IgG1 isotype con-
trol AB (Figure 6b). This indicates, that the RNA in the EVs 
bound to the lipid patches remains trapped in our system, 
opening up a future downstream analysis, e.g., by targeted 
retrieval of patches via micropipettes, as previously shown for 
CTCs.[72,73]
2.7. EV Capture from Patient Sample
To validate our platform further we strived to demonstrate 
detection from EVs isolated from blood samples of cancer 
patients. For this, serum was collected from three pancreatic 
cancer patients and EVs were enriched using SEC (qEV35 nm 
columns). All fractions were characterized by NTA; BCA and 
then incubated on lipid-patch arrays functionalized with CD63 
AB. Successful capture of EVs was confirmed by subsequent 
staining with EpCAM AB, recognizing cancer-derived EVs[19] 
(Figure 7b).
In all three patients, EVs could successfully be detected on 
the CD63 functionalized patches by EpCAM immunostaining, 
while no signal was obtained from negative control fractions 
(Figure S7, Supporting Information). To test if EV nucleic 
acid cargo is retained on the lipid array, we stained for RNA 
Adv. Mater. 2021, 2008493
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(Figure  7b; and Figure S8, Supporting Information). The 
staining is supporting the assumption of EV cargo being 
retained, further corroborating the data on RNA retention in 
the previous section. Overall, the successful capture of cancer-
associated EVs from the patient samples underlines the poten-
tial of our platform for clinical applications.
3. Conclusion
Despite the large variety of new isolating or detecting methods 
that try to conquer the challenges of EV isolation or detec-
tion,[10] there is still no approved EV isolation, or detection 
method introduced for clinical use. This is partly because of 
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Figure 6. EV capture from complex samples and RNA retention. a) Fluorescence microscopy images of CD63 antibody- and IgG1 (isotype control) 
antibody-functionalized lipid patches after capture of EVs from purified, unpurified and spiked samples and subsequent immunostaining against 
EpCAM (anti-EpCAM antibody from rabbit, Alexa-647 (in purple) conjugated anti-rabbit antibody). MCF7-derived EVs result in a strong fluorescence 
signal from purified and unpurified sample. Incubation of unpurified HT1080 derived EVs results (as expected) in only weak fluorescence. Incubation 
of HT1080 conditioning medium spiked with purified MCF7-derived EVs also induces a fluorescence signal on the lipid-patch array. The IgG1 (isotype 
control) carrying lipid patches remain without fluorescence for all cases (negative control). This shows that specific detection out of complex medium 
is possible, and the signal arises not from unspecific interactions with other components of the sample medium. b) Staining with a nucleic acid dye 
(SYTO in green) reveals that all CD63 antibody-functionalized lipid arrays contain nucleic acids, while arrays carrying IgG1 (isotype control) antibodies 
do not. This shows, that RNA cargo present in the EVs remains in the lipid-patch arrays after capture, thus could be used for downstream analysis. 
All scale bars equal 50 µm.
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the high standard that such a system would need to fulfill, as 
it should be accurate, specific, reliable, rapid, easy to handle, 
inexpensive, and applicable for different types of EVs.[24] Toward 
this goal, we presented our new approach of utilizing dip-pen 
nanolithography created lipid patches arranged into microscale 
arrays for EV capture. The platform can detect EVs from puri-
fied and unpurified samples rapidly (overall processing times of 
2 h instead of standard processes that require up to 17 h) and 
works with minimal sample volumes (30–50  µL), minimizing 
costs for processing and material consumption. It was shown 
that the platform can reliably target EVs highly accurate and 
specific, out of a background of complex media and in mixtures 
containing off-target types of EVs. The obtained sensitivity is 
matching that of other ultrasensitive methods (comparison to 
selected EV capture methods in Table S1, Supporting Infor-
mation),[74–81] spanning the whole range of physiological rel-
evant EV concentrations. Furthermore, the lipid arrays were 
also demonstrated to retain the RNA (and thus probably the 
other biomaterial cargo) of EVs in the system, which shows 
the platforms potential to isolate RNA for downstream anal-
ysis. Finally, the detection of cancer-associated EVs from pan-
creatic cancer patients validates our platforms robustness and 
potential for clinical application. The ABs used in the platform 
can be readily exchanged for targeting different types of EVs 
without need for adjustments at the general approach, ena-
bling a high versatility. By incorporation of the platform into 
microfluidic chips, even easier handling could be achieved.[82] 
In combination with full-fledged lab-on-chip approaches, the 
lipid-array-based EV capture could be used in point-of-care or 
even at bedside environment.[83–85] In conclusion, the presented 
novel EV capture platform offers a high potential for diagnostic 
and research applications as demonstrated for, but not limited 
to cancer, as many other applications involving EVs could be 
addressed, alike.
4. Experimental Section
Phospholipids: 20  mg  mL−1 (25.4  ×  10−3  m) of 1,2-dioleoyl-sn-glycero-
3-phosphocholine (DOPC; Avanti Polar Lipids, USA) and 5 mol% of 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(cap biotinyl) (Biotin-PE; 
Avanti Polar Lipids, USA) in DOPC were used in patterning the lipid 
patches. All lipids were purchased from Avanti Polar Lipids, USA.
Patterning of Lipid Arrays by DPN: The lipid micropattern patches were 
fabricated by DPN 5000 (Nanoink Inc., USA) with the B-side of M-type 
cantilever array which has 12 tips with a 66 µm pitch (Advanced Creative 
Solutions Technology (ACST, USA). Tips were homogenously coated 
by dipping into the matched inkwells (ACST, USA) for 5 min with a 
controlled 60% relative humidity (RH). The inkwell was loaded with 2 µL 
of the desired phospholipid mixture (20 mg mL−1 in chloroform) in each 
reservoir and chloroform evaporated in a vacuum desiccator (15 min) or 
overnight in a damp-proof box. Afterward, the coated tips were moved 
to the desired location on the substrate (either glass cover slips cleaned 
by sonification subsequently with chloroform, isopropanol and DI water, 
or 2-methacryloyloxyethyl phosphorylcholine (MPC) copolymer covered 
slides[31]) and lipid-patch arrays were written. The patches (30 × 30 µm2) 
were written at 30–40% RH with hatch lines of 0.5  µm pitch and a 
writing speed of 0.2–2 µm s−1.
Purification of Extracellular Vesicles: MCF7 cells, HT1080 cells, and 
3T3 fibroblasts were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM, Life Technologies, Germany) supplemented with 10% 
exosome-depleted FBS (System Biosciences, USA) under standard 
cell-culture conditions (37  °C and 5% CO2) for 48 h. Then, condition 
medium was centrifuged at 500g for 10 min to remove suspended cells. 
The condition medium was then filtered by a 0.22  µm Steriflip filter 
(Millipore, USA) on ice for removing cell debris. In order to do further 
enrichment of EVs and reduce the amount of the condition medium, 
it was centrifuged with Amicon 100  kDa cut-off Ultrafilter (Millipore, 
USA) at 5000g for 30 min. The filtered medium was discarded and the 
EVs were fully recovered by using 200  mL of cold phosphate buffered 
saline (PBS) into the filter device to sweep the filter membranes. The 
enriched EVs sample was stained with the PKH dye (Sigma-Aldrich, 
USA), which is a lipophilic fluorescent dye, and then centrifuged again 
at 5000g for 30 min for removing unbounding dyes. All centrifuge 
and filtering steps were performed at 4  °C. The labeled EVs were fully 
recovered from the spin column and loaded into a qEVoriginal SEC 
column (IZON, UK). Fractions of 500 µL each were collected according 
to the recommendations of the supplier (meaning that the first 3  mL 
void volume was discarded as the EV fraction is expected to appear at 
(3.75  ±  0.25) mL. “Fraction 1” corresponds to the first 500  µL sample 
collected after the void volume passed the column. Additional fractions 
refer to the subsequent volumes of 500  µL passing, respectively. SEC 
was done at room temperature, collected fractions were immediately 
transferred on ice or stored at −80 °C after collection.
Micro BCA Analysis: 150 µL of each standard and fractions were loaded 
into a microplate’s well and replicated twice. Each well was added with 
150 µL of the working reagent and mixed thoroughly on a plate shaker 
for 30 s. The loaded microplate was then incubated for 2 h at 37 °C. The 
result was measured for absorbance at 562 nm on a plate reader.
Nanoparticle Tracking Analysis (NTA): EV concentration and size 
distribution were determined by ZetaView (Particle Metrix, Germany). 
Samples were diluted consecutively with ddH20 to receive an optimal 
concentration of 100–200 particle counts. One mL of diluted sample 
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Figure 7. EV capture from patient samples. a) NTA/BCA data on the dif-
ferent fractions obtained from 3 cancer patients. The error bars report the 
SD. b) Fluorescence microscopy images of CD63 antibody-functionalized 
lipid patches after capture of EVs from fraction 5 of patient I and sub-
sequent immunostaining against EpCAM (anti-EpCAM antibody from 
rabbit, Alexa-647 (in purple) conjugated anti-rabbit antibody) and c) 
staining for nucleic acid (SYTO in green) confirming RNA cargo reten-
tion. Scale bars equal 50 µm.
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was injected into the NTA. The size distribution was measured in scatter 
mode and Zeta potential was measured in Zeta Potential mode using set 
up: Sensitivity 85; Min size 20 nm; Max size 1000 nm; Min Brightness 10. 
The ZetaView determines the size of vesicles based on Brownian motion 
and this principle is used for analysis of nanometer-sized particles.[86]
Vesicles Labeling with PKH Dyes: After the ultrafilter, Diluent C buffer 
(Sigma-Aldrich, USA) was added into condensed medium (total volume 
1  mL) and then mixed well with 1  mL of labeling solution (consisting 
of 6  µL of the PKH67 or PKH26 ethanolic dye (as obtained from 
Sigma-Aldrich, USA) in 1 mL Diluent C). The mixture was incubated for 
5 min at room temperature and to stop the staining reaction, 1% BSA 
(Sigma-Aldrich, USA) in PBS buffer (2 mL) was added for 1 min.
EV Chip Functionalization and Capturing: The micropattern lipid 
patches on EV chip were coated by 1% streptavidin (Sigma-Aldrich, 
USA) in 10% BSA (Sigma-Aldrich, USA) in PBS for 30 min and washed 
3 times by pipetting on and off 100 µL of PBS to wash away unbound 
streptavidin. The streptavidin-lipid patches were then incubated 
with 100  µL of 0.01  µg  µL−1 solution of desired biotinylated antibody 
((Biotinylated anti-EpCAM (VU-1D9, abcam, UK), biotinylated anti-CD63 
(MEM-259, abcam, UK), biotinylated anti-CD63 (Rabbit antimouse; 
MyBioSource, USA) and biotinylated Mouse-IgG1 isotype control 
(MOPC-21, abcam, UK)) in 10% BSA in PBS for 30 min and washed 3 
times by pipetting on and off 100 µL of PBS, rendering the EV chip ready 
to use. The purified EVs were diluted to 102–108 times with 4% EDTA-
free Protease Inhibitor cocktail (Sigma-Aldrich, USA) in cold PBS. The 
purified and diluted EVs fraction (50 µL) was loaded onto the prepared 
EV chip for 1 h at 4  °C. After incubation, the sample was washed by 
dipping it into 100  mL of DI water for 3 times. Samples where then 
imaged with a fluorescence microscope.
EV Dilution Series: For the dilution series experiments, MCF7 EVs 
were purified as described above and EV concentration was determined 
by ExoELISA (see next section). Then the EV samples were diluted 
to the respective concentration and incubated on lipid patch arrays 
functionalized with the respective ABs as described above. After EV 
capture, the samples were stained and analyzed by fluorescence 
microscopy. Fluorescence intensities for 5 patches on each array were 
quantified with the onboard software of the microscope (NIS-Elements, 
Nikon, Germany). For each AB the experiment was done in triplicate 
with independently prepared EV samples.
ExoELISA: The ExoELISA-Ultra CD63 kit (System Biosciences, USA) 
was used for calculating EV concentration for the purified samples 
used in the dilution series. 50  µL of EV samples and standards were 
loaded into microtiter plate and incubated at 37  °C for 1 h. After 
incubation, the reacted wells were washed 3 times by 100 µL of 1× wash 
buffer for each well. 50 µL of diluted CD63 primary antibody (1:100) in 
blocking buffer was added to each reacted well and incubated at room 
temperature for 1 h with shaking (parameter). Before adding 50  µL of 
3,3”,5,5”-tetramethylbenzidine (TMB) substrate to each reacted well, 
washing step with 1× wash buffer was repeated. After incubating with 
TMB substrate at room temperature for 5–15 min with shaking, 50 µL of 
stop buffer was loaded to each well and read immediately by an ELISA 
reader at 450 nm wavelength.
Capture of EVs from Unpurified Condition Medium: After incubating 48 h, 
the condition medium was centrifuged at 500g for 10 min in order to get 
rid of the big projects (suspensive cells, cell debris, etc.) and subsequently 
filtered by 0.22 µm Steriflip filter on ice. The prepared EV chip was directly 
immersed in the filtered medium in a petri dish (VWR, USA) at 4 °C for 
1  h. The chip was washed three times by dipping into 100  mL DI water 
after incubation and imagined with a fluorescence microscope.
Spiking Experiment: The MCF7 EVs were purified by SEC column 
(qEVoriginal, IZON LtD) as described above. 500  µL of purified MCF7 
EVs was spiked into 12 mL of the condition medium of HT1080 which was 
cultured for 48 h. The condition medium of HT1080 was centrifuged at 500g 
for 10 min and filtered by 0.22 µm PES filter (Millipore, USA) in advance. 
The purified MCF7 EVs and HT1080 condition medium were mixed well and 
poured onto functionalized EV chips placed in a petri dish on ice for 1 h. 
After capturing, the EV chips were washed with DI water (three times by 
dipping into 100 mL) and then analyzed via optical microscopy.
Immunostaining: 0.5  µg of primary anti-EpCAM antibody (Rabbit 
polyclonal, Abcam, UK) admixed with 50  µL of 10% BSA in PBS was 
incubated on the captured EV chip at 4  °C for 1 h and washed three 
times by dipping into 100  mL of DI water. Then, 0.5  µg of secondary 
anti-rabbit IgG Alexa Fluor 647 (donkey polyclonal, Abcam, UK) mixed 
with 50 µL of 10% BSA in PBS was incubated at 4 °C for 1 h and then 
washed three times by dipping into 100 mL DI water, and imagined with 
a fluorescence microscope.
Fluorescent Labeling of RNA: SYTO RNASelect Green Fluorescent 
Cell Stain (5 × 10−3 m, Thermo Fisher Scientific, USA) was first diluted 
to 5 × 10−9 m into PBS then immediately incubated onto captured-EV 
chips for 20 min at room temperature. After incubation, the EV 
chips were washed by incubation with 100  µL of DI water two times 
for 5 min each. Then, the EV chips were imagined with fluorescent 
microscopy.
Detection of Cancer-Associated EVs from Patient Samples: Serum 
samples were collected from pancreatic cancer patients with approval 
of the local ethics committee at the University of Freiburg following 
informed consent from the donors. The serum samples were 
centrifuged at 1650g for 15 min according to the recommendations 
of the vacutainer supplier. The platelets-free serum was transferred 
into fresh tubes and frozen at –80 °C. 500 µL of cell-free serum were 
subjected to SEC, using qEV35 original columns (IZON, France). For 
each patient, 7 subsequent fractions (Fraction 1–7) of 500 µL each were 
collected after the void volume of 3 mL has passed the column. Also 
500  µL of the void volume was sampled (Void) as control. 80  µL of 
each fraction was loaded onto prepared EV chips and incubated for 
1 h at 4 °C. The EV chip was washed three times by dipping into 100 mL 
of DI water after incubation and then immunostained as described 
above. For two patient samples, RNA staining was performed as 
described above. After staining procedures, samples were imaged with 
fluorescence microscopy.
Optical Microscopy: The images were recorded using an Upright 
microscope (Eclipse 80i, Nikon Instruments Europe B.V., Germany) 
using onboard software (NIS-Elements, Nikon, Germany). Illumination 
for fluorescence microscopy was an Intensilight (Nikon, Germany) and 
filter cubes for TexasRed (excitation/emission wavelength: 559/630 nm, 
color-coded red) FITC (475/530  nm, color-coded green), and Cy5 
(604/712 nm, color-coded purple) were used.
Electron Microscopy: A FEI Titan 80–300 aberration (image) 
corrected transmission electron microscope (TEM) operating at 300 
KV acceleration voltage and equipped with a high-angle annular dark-
field (HAADF) detector (Fischione) for STEM imaging, and a S-UTW 
EDX detector (EDAX Inc.). TEM samples were prepared by direct 
printing. The lipid micropattern patches were directly fabricated on a 
silicon nitride (SiN) 20  nm thick membrane TEM window grid with 
9 electron-transparent windows, 8 of dimensions 100  ×  100  µm2, 
and one of 100  ×  350  µm2, by writing a lipid mixture of DOPC and 
Biotin-Cap-PE with a DPN 5000 system (Nanoink Inc., USA). The 
details of printing condition can be seen above section (Patterning 
of lipid arrays by DPN). The patterns on the SiN grid were coated 
1% streptavidin and then incubated with 0.01  µg  µL−1 of primary 
biotinylated-antibody from rabbit (Abcam, UK). After washing, the 
primary antibody-lipid arrays were incubated with secondary antibody 
conjugated with 2  nm gold particles (Abcam, UK) for 1 h at room 
temperature. Then, unbound secondary antibodies were washed away 
by pipetting on and off with DI water three times. The lipid arrays 
were ready for imaging by STEM. Au NPs were counted using ImageJ 
software where Intermodes threshold in the multithreshold option 
with a median filter of 2.0 pixel were used to eliminate the background 
noise before counting the nanoparticles at different magnifications 
(Figure S4, Supporting Information).
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